New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 21, 2013
07:26 EDTVRX, OMPIValeant price target raised to $80 from $70 at RBC Capital
RBC Capital increased its price target on Valeant (VRX) to reflect the Obagi (OMPI) acquisition, higher conviction levels for IDP-108 launch and an expected increase to 2013 guidance during the Q1 results conference call. The firm doesn't see the Obagi deal as transformational for Valeant but does expect it to generate at least $40M in synergies. RBC maintains an Outperform rating on Valeant.
News For VRX;OMPI From The Last 14 Days
Check below for free stories on VRX;OMPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 16, 2014
08:34 EDTVRXPiper Jaffray tech and biopharma analysts hold analyst/industry conference call
Technical Analyst Johnson, along with BioPharma Analysts, discuss the recent downturn in the biotech and specialty pharmaceuticals industries on an Analyst/Industry conference call to be held on April 17 at 10 am.
07:19 EDTVRXValeant top pick in specialty pharmaceutical space, says Cantor
Subscribe for More Information
April 8, 2014
07:08 EDTVRXDrug deals increase to new high, Bloomberg says
M&A activity in the specialty pharmaceuticals industry has reached a new high after Mallinckrodt (MNK) recently bought Questcor (QCOR) for $5.6B, reported Bloomberg. Drugmakers from Actavis (ACT) to Valeant (VRX) are widening their suites of drugs through takeovers that immediately increased earnings with the help of lower corporate tax rates in countries such as Ireland. Reference Link
April 7, 2014
14:09 EDTVRXSun Pharmaceutical agrees to acquire generic drugmaker Ranbaxy
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use